文献速递前列腺增生与排尿功能障碍

UNBLOCS试验:TURP与铥激光前列腺汽化切除术治疗良性前列腺梗阻的成本效果分析

The cost-effectiveness of transurethral resection of the prostate vs thulium laser transurethral vaporesection of the prostate in the UNBLOCS randomised controlled trial for benign prostatic obstruction.
PubMed 文献 · BJU Int · 2020-08-10

UNBLOCS随机对照试验在英国7家中心纳入410例因良性前列腺梗阻(BPO)需手术的男性,1:1随机接受TURP或ThuVARP,随访12个月。结论认为TURP仍是BPO高度成本有效的治疗选择。

要点

  • TURP与ThuVARP的12个月次级护理成本相近,TURP略低£9(95%CI -£376, £359)。
  • ThuVARP手术时间平均比TURP长21分钟。

核心结论

  • TURP相比ThuVARP在12个月内成本略低且QALY相似,仍为BPO的高度成本有效治疗。

研究设计与样本

  • 英国7家中心(4家大学教学医院、3家地区综合医院)开展的随机对照试验,纳入410例≥18岁因BPO导致困扰性LUTS或尿潴留且适合手术的男性,麻醉下1:1随机接受TURP或ThuVARP。

主要发现

  • TURP组12个月调整后平均次级护理成本为£4244,比ThuVARP组的£4253低£9(95%CI -£376, £359)。
  • ThuVARP手术时间平均比TURP长21分钟。
  • 调整后QALY差异为0.01 favouring TURP(95%CI -0.01, 0.04),两组相似。

关键数值与推荐

  • QALY基于基线、3个月和12个月完成的EQ-5D-5L问卷计算;资源使用采用英国参考成本估值。

临床怎么用

  • 激光手术预期的缩短住院时间及降低成本优势在研究期间未实现。
  • ThuVARP手术时间较长,需考虑患者麻醉时间增加及服务提供角度的影响。
  • TURP仍是BPO男性高度成本有效的治疗选择。

局限性

  • 激光手术预期减少住院时间及成本的优势在研究期间未实现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the cost-effectiveness of the current 'gold standard' operation of transurethral resection of the prostate (TURP) compared to the new laser technique of thulium laser transurethral vaporesection of the prostate (ThuVARP) in men with benign prostatic obstruction (BPO) within the UK National Health Service (NHS). PATIENTS AND METHODS: The trial was conducted across seven UK centres (four university teaching hospitals and three district general hospitals). A total of 410 men aged ≥18 years presenting with either bothersome lower urinary tract symptoms (LUTS) or urinary retention secondary to BPO, and suitable for surgery, were randomised (whilst under anaesthetic) 1:1 to receive the TURP or ThuVARP procedure. Resource use in relation to the operation, initial inpatient stay, and subsequent use of NHS services was collected for 12 months from randomisation (equivalent to primary effectiveness outcome) using hospital records and patient questionnaires. Resources were valued using UK reference costs. Quality adjusted life years (QALYs) were calculated from the EuroQoL five Dimensions five Levels (EQ-5D-5L) questionnaire completed at baseline, 3- and 12-months. Total adjusted mean costs, QALYs and incremental Net Monetary Benefit statistics were calculated: cost-effectiveness acceptability curves and sensitivity analyses addressed uncertainty. RESULTS: The total adjusted mean secondary care cost over the 12 months in the TURP arm (£4244) was £9 (95% CI -£376, £359) lower than the ThuVARP arm (£4253). The ThuVARP operation took on average 21 min longer than TURP. The adjusted mean difference of QALYs (0.01 favouring TURP, 95% CI -0.01, 0.04) was similar between the arms. There is a 76% probability that TURP is the cost-effective option compared with ThuVARP at the £20 000 per QALY willingness to pay threshold used by National Institute for Health and Care Excellence (NICE). CONCLUSION: One of the anticipated benefits of the laser surgery, reduced length of hospital stay with an associated reduction in cost, did not materialise within the study. The longer duration of the ThuVARP procedure is important to consider, both from a patient perspective in terms of increased time under anaesthetic, and from a service delivery perspective. TURP remains a highly cost-effective treatment for men with BPO.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Noble SM, Ahern AM, Worthington J, et al. The cost-effectiveness of transurethral resection of the prostate vs thulium laser transurethral vaporesection of the prostate in the UNBLOCS randomised controlled trial for benign prostatic obstruction. BJU Int. 2020. PMID: 32558178. doi:10.1111/bju.15138

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。